{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T17:55:46Z","timestamp":1794333346889,"version":"4.9.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T00:00:00Z","timestamp":1775260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":60,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972293"],"award-info":[{"award-number":["81972293"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82003088"],"award-info":[{"award-number":["82003088"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82372643"],"award-info":[{"award-number":["82372643"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-71403-1","type":"journal-article","created":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T16:24:05Z","timestamp":1775319845000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Inhibition of circulating glycocholic acid-regulated signaling potentiates immune checkpoint therapy in colorectal cancer"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7079-0771","authenticated-orcid":false,"given":"Senlin","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushuai","family":"Mi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Quan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijuan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyang","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjun","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2354-4735","authenticated-orcid":false,"given":"Xinxiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9805-6330","authenticated-orcid":false,"given":"Ping","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9335-2114","authenticated-orcid":false,"given":"WanJun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuping","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianqiang","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5642-4000","authenticated-orcid":false,"given":"Dawei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,4]]},"reference":[{"key":"71403_CR1","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/s41575-019-0189-8","volume":"16","author":"N Keum","year":"2019","unstructured":"Keum, N. & Giovannucci, E. Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies. Nat. Rev. Gastroenterol. Hepatol. 16, 713\u2013732 (2019).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"71403_CR2","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/s41575-022-00661-3","volume":"19","author":"A Shaukat","year":"2022","unstructured":"Shaukat, A. & Levin, T. R. Author correction: current and future colorectal cancer screening strategies. Nat. Rev. Gastroenterol. Hepatol. 19, 551 (2022).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"71403_CR3","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41571-022-00601-9","volume":"19","author":"H Yamaguchi","year":"2022","unstructured":"Yamaguchi, H., Hsu, J. M., Yang, W. H. & Hung, M. C. Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics. Nat. Rev. Clin. Oncol. 19, 287\u2013305 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"71403_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01720-2","volume":"22","author":"S Vivekanandhan","year":"2023","unstructured":"Vivekanandhan, S. et al. Immunotherapies in rare cancers. Mol. Cancer 22, 23 (2023).","journal-title":"Mol. Cancer"},{"key":"71403_CR5","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2023.02.014","volume":"41","author":"C Tay","year":"2023","unstructured":"Tay, C., Tanaka, A. & Sakaguchi, S. Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy. Cancer Cell 41, 450\u2013465 (2023).","journal-title":"Cancer Cell"},{"key":"71403_CR6","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/s41575-019-0126-x","volume":"16","author":"K Ganesh","year":"2019","unstructured":"Ganesh, K. et al. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat. Rev. Gastroenterol. Hepatol. 16, 361\u2013375 (2019).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"71403_CR7","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.cmet.2019.04.002","volume":"30","author":"X Ma","year":"2019","unstructured":"Ma, X. et al. Cholesterol induces CD8(+) T cell exhaustion in the tumor microenvironment. Cell Metab. 30, 143\u2013156.e145 (2019).","journal-title":"Cell Metab."},{"key":"71403_CR8","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/s42255-020-0174-0","volume":"2","author":"B Huang","year":"2020","unstructured":"Huang, B., Song, B. L. & Xu, C. Cholesterol metabolism in cancer: mechanisms and therapeutic opportunities. Nat. Metab. 2, 132\u2013141 (2020).","journal-title":"Nat. Metab."},{"key":"71403_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01316-8","volume":"20","author":"L Xia","year":"2021","unstructured":"Xia, L. et al. The cancer metabolic reprogramming and immune response. Mol. Cancer 20, 28 (2021).","journal-title":"Mol. Cancer"},{"key":"71403_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16079-x","volume":"11","author":"C Coutzac","year":"2020","unstructured":"Coutzac, C. et al. Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer. Nat. Commun. 11, 2168 (2020).","journal-title":"Nat. Commun."},{"key":"71403_CR11","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.immuni.2018.03.014","volume":"48","author":"C Sun","year":"2018","unstructured":"Sun, C., Mezzadra, R. & Schumacher, T. N. Regulation and function of the PD-L1 checkpoint. Immunity 48, 434\u2013452 (2018).","journal-title":"Immunity"},{"key":"71403_CR12","doi-asserted-by":"crossref","unstructured":"Du, L. et al. beta-Catenin induces transcriptional expression of PD-L1 to promote glioblastoma immune evasion. J. Exp. Med. 217, e20191115 (2020).","DOI":"10.1084\/jem.20191115"},{"key":"71403_CR13","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.immuni.2017.11.016","volume":"47","author":"MA Coelho","year":"2017","unstructured":"Coelho, M. A. et al. Oncogenic RAS signaling promotes tumor immunoresistance by stabilizing PD-L1 mRNA. Immunity 47, 1083\u20131099 e1086 (2017).","journal-title":"Immunity"},{"key":"71403_CR14","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41422-018-0124-5","volume":"29","author":"Y Yang","year":"2019","unstructured":"Yang, Y. et al. Palmitoylation stabilizes PD-L1 to promote breast tumor growth. Cell Res. 29, 83\u201386 (2019).","journal-title":"Cell Res."},{"key":"71403_CR15","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/s41586-020-2609-x","volume":"586","author":"T Muthusamy","year":"2020","unstructured":"Muthusamy, T. et al. Serine restriction alters sphingolipid diversity to constrain tumour growth. Nature 586, 790\u2013795 (2020).","journal-title":"Nature"},{"key":"71403_CR16","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41551-019-0375-6","volume":"3","author":"H Yao","year":"2019","unstructured":"Yao, H. et al. Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours. Nat. Biomed. Eng. 3, 306\u2013317 (2019).","journal-title":"Nat. Biomed. Eng."},{"key":"71403_CR17","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1053\/j.gastro.2011.10.028","volume":"142","author":"S Modica","year":"2012","unstructured":"Modica, S. et al. Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis. Gastroenterology 142, 355\u2013365.e351-354 (2012).","journal-title":"Gastroenterology"},{"key":"71403_CR18","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/s41575-020-00404-2","volume":"18","author":"L Sun","year":"2021","unstructured":"Sun, L., Cai, J. & Gonzalez, F. J. The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer. Nat. Rev. Gastroenterol. Hepatol. 18, 335\u2013347 (2021).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"71403_CR19","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.semcancer.2020.10.003","volume":"73","author":"S Ocvirk","year":"2021","unstructured":"Ocvirk, S. & O\u2019Keefe, S. J. D. Dietary fat, bile acid metabolism and colorectal cancer. Semin Cancer Biol. 73, 347\u2013355 (2021).","journal-title":"Semin Cancer Biol."},{"key":"71403_CR20","doi-asserted-by":"publisher","first-page":"S87","DOI":"10.5604\/01.3001.0010.5501","volume":"16","author":"A Di Ciaula","year":"2017","unstructured":"Di Ciaula, A. et al. Bile acids and cancer: direct and environmental-dependent effects. Ann. Hepatol. 16, S87\u2013S105 (2017).","journal-title":"Ann. Hepatol."},{"key":"71403_CR21","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.cell.2019.01.036","volume":"176","author":"T Fu","year":"2019","unstructured":"Fu, T. et al. FXR regulates intestinal cancer stem cell proliferation. Cell 176, 1098\u20131112.e1018 (2019).","journal-title":"Cell"},{"key":"71403_CR22","doi-asserted-by":"crossref","unstructured":"Sun, L., Cai, J. & Gonzalez, F.J. The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer. Nat. Rev. Gastroenterol. Hepatol. 18, 335\u2013347 (2021).","DOI":"10.1038\/s41575-020-00404-2"},{"key":"71403_CR23","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.cmet.2009.09.009","volume":"10","author":"JK Kemper","year":"2009","unstructured":"Kemper, J. K. et al. FXR acetylation is normally dynamically regulated by p300 and SIRT1 but constitutively elevated in metabolic disease states. Cell Metab. 10, 392\u2013404 (2009).","journal-title":"Cell Metab."},{"key":"71403_CR24","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.bbadis.2018.05.011","volume":"1865","author":"J Li","year":"2019","unstructured":"Li, J. & Dawson, P. A. Animal models to study bile acid metabolism. Biochim. Biophys. Acta Mol. Basis Dis. 1865, 895\u2013911 (2019).","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"71403_CR25","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/s41577-024-01057-x","volume":"24","author":"MH Lee","year":"2024","unstructured":"Lee, M. H. et al. How bile acids and the microbiota interact to shape host immunity. Nat. Rev. Immunol. 24, 798\u2013809 (2024).","journal-title":"Nat. Rev. Immunol."},{"key":"71403_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-04745-5","volume":"13","author":"J Yu","year":"2022","unstructured":"Yu, J. et al. Activation of FXR and inhibition of EZH2 synergistically inhibit colorectal cancer through cooperatively accelerating FXR nuclear location and upregulating CDX2 expression. Cell Death Dis. 13, 388 (2022).","journal-title":"Cell Death Dis."},{"key":"71403_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-02819-w","volume":"11","author":"J Yu","year":"2020","unstructured":"Yu, J. et al. Farnesoid X receptor antagonizes Wnt\/beta-catenin signaling in colorectal tumorigenesis. Cell Death Dis. 11, 640 (2020).","journal-title":"Cell Death Dis."},{"key":"71403_CR28","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1124\/jpet.108.145409","volume":"328","author":"RR Maran","year":"2009","unstructured":"Maran, R. R. et al. Farnesoid X receptor deficiency in mice leads to increased intestinal epithelial cell proliferation and tumor development. J. Pharm. Exp. Ther. 328, 469\u2013477 (2009).","journal-title":"J. Pharm. Exp. Ther."},{"key":"71403_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-79916-5","volume":"11","author":"T Miyazaki","year":"2021","unstructured":"Miyazaki, T. et al. Novel FXR agonist nelumal A suppresses colitis and inflammation-related colorectal carcinogenesis. Sci. Rep. 11, 492 (2021).","journal-title":"Sci. Rep."},{"key":"71403_CR30","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/s41579-022-00805-x","volume":"21","author":"SL Collins","year":"2023","unstructured":"Collins, S. L., Stine, J. G., Bisanz, J. E., Okafor, C. D. & Patterson, A. D. Bile acids and the gut microbiota: metabolic interactions and impacts on disease. Nat. Rev. Microbiol. 21, 236\u2013247 (2023).","journal-title":"Nat. Rev. Microbiol."},{"key":"71403_CR31","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41586-020-2396-4","volume":"582","author":"M Funabashi","year":"2020","unstructured":"Funabashi, M. et al. A metabolic pathway for bile acid dehydroxylation by the gut microbiome. Nature 582, 566\u2013570 (2020).","journal-title":"Nature"},{"key":"71403_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36089-9","volume":"14","author":"L Sun","year":"2023","unstructured":"Sun, L. et al. Bile salt hydrolase in non-enterotoxigenic Bacteroides potentiates colorectal cancer. Nat. Commun. 14, 755 (2023).","journal-title":"Nat. Commun."},{"key":"71403_CR33","doi-asserted-by":"publisher","first-page":"6251","DOI":"10.4049\/jimmunol.0803978","volume":"183","author":"P Vavassori","year":"2009","unstructured":"Vavassori, P., Mencarelli, A., Renga, B., Distrutti, E. & Fiorucci, S. The bile acid receptor FXR is a modulator of intestinal innate immunity. J. Immunol. 183, 6251\u20136261 (2009).","journal-title":"J. Immunol."},{"key":"71403_CR34","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1158\/2326-6066.CIR-17-0672","volume":"7","author":"W You","year":"2019","unstructured":"You, W. et al. Farnesoid X receptor constructs an immunosuppressive microenvironment and sensitizes FXR(high)PD-L1(low) NSCLC to anti-PD-1 immunotherapy. Cancer Immunol. Res. 7, 990\u20131000 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"71403_CR35","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/s41419-020-02819-w","volume":"11","author":"J Yu","year":"2020","unstructured":"Yu, J. et al. Farnesoid X receptor antagonizes Wnt\/\u03b2-catenin signaling in colorectal tumorigenesis. Cell Death Dis. 11, 640 (2020).","journal-title":"Cell Death Dis."},{"key":"71403_CR36","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1038\/s41556-022-01002-x","volume":"24","author":"KC Kao","year":"2022","unstructured":"Kao, K. C., Vilbois, S., Tsai, C. H. & Ho, P. C. Metabolic communication in the tumour-immune microenvironment. Nat. Cell Biol. 24, 1574\u20131583 (2022).","journal-title":"Nat. Cell Biol."},{"key":"71403_CR37","doi-asserted-by":"crossref","unstructured":"Liu, X. et al. Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer. Nature 588, 693\u2013698 (2020).","DOI":"10.1038\/s41586-020-2911-7"},{"key":"71403_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-14-632","volume":"14","author":"NA Mabbott","year":"2013","unstructured":"Mabbott, N. A., Baillie, J. K., Brown, H., Freeman, T. C. & Hume, D. A. An expression atlas of human primary cells: inference of gene function from coexpression networks. BMC Genomics 14, 632 (2013).","journal-title":"BMC Genomics"},{"key":"71403_CR39","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1158\/2159-8290.CD-19-1409","volume":"10","author":"DY Torrejon","year":"2020","unstructured":"Torrejon, D. Y. et al. Overcoming genetically based resistance mechanisms to PD-1 blockade. Cancer Discov. 10, 1140\u20131157 (2020).","journal-title":"Cancer Discov."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71403-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71403-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71403-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T22:34:54Z","timestamp":1780439694000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71403-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,4]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["71403"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-71403-1","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,4]]},"assertion":[{"value":"20 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4893"}}